Completed
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk
I8F-MC-GPGM - ClinicalTrials.gov - NCT03730662
The purpose of the trial is to assess the efficacy and safety of tirzepatide taken once a week to insulin glargine taken once daily in participants with type 2 diabetes and increased cardiovascular risk.
How long will I be in the trial?
The study will last about 108 weeks and may include up to 30 visits.
Completed
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk
I8F-MC-GPGM - ClinicalTrials.gov - NCT03730662
The purpose of the trial is to assess the efficacy and safety of tirzepatide taken once a week to insulin glargine taken once daily in participants with type 2 diabetes and increased cardiovascular risk.
How long will I be in the trial?
The study will last about 108 weeks and may include up to 30 visits.
Key Requirements
Age :
18+
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participant must have type 2 diabetes mellitus (T2DM)
Participant must be on stable treatment dose of at least 1 and no more than 3 oral antihyperglycemic drugs
Participant must have increased risk for cardiovascular events
Participant must be of stable weight
Participants must NOT
Participant must not have type 1 diabetes mellitus (T1DM)
Participant must not have pancreatitis
Participant must not have disorders with slowed emptying of the stomach contents, or have had any stomach surgeries for the purpose of weight loss
Participant must not have acute or chronic hepatitis or symptoms of any other liver disease
Participant must not have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months
Participant must not have been taking weight loss drugs including over-the-counter medications during the last 3 months
Trial Summary
Conditions the trial is for
Adult Type 2 Diabetes
What the trial is testing?
Tirzepatide, Insulin Glargine
Could I receive a Placebo?
no
Enrollment Goal
1878
Trial Dates
November 2018 - April 2021
Trial Phase
3
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participant must have type 2 diabetes mellitus (T2DM)
Participant must be on stable treatment dose of at least 1 and no more than 3 oral antihyperglycemic drugs
Participant must have increased risk for cardiovascular events
Participant must be of stable weight
Participants must NOT
Participant must not have type 1 diabetes mellitus (T1DM)
Participant must not have pancreatitis
Participant must not have disorders with slowed emptying of the stomach contents, or have had any stomach surgeries for the purpose of weight loss
Participant must not have acute or chronic hepatitis or symptoms of any other liver disease
Participant must not have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months
Participant must not have been taking weight loss drugs including over-the-counter medications during the last 3 months
Trial Summary
Conditions the trial is for
Adult Type 2 Diabetes
What the trial is testing?
Tirzepatide, Insulin Glargine
Could I receive a Placebo?
no
Enrollment Goal
1878
Trial Dates
November 2018 - April 2021
Trial Phase
3
Not the right fit? Sign up to receive updates on new trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
Adult Type 2 Diabetes Resources
